The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Fulvestrant with or without the cyclin-dependent kinase 7 (CDK7) inhibitor samuraciclib in advanced hormone receptor positive (HR+) breast cancer after CDK4/6 inhibition: Phase II SUMIT-BC study.
 
Sonia Pernas
Consulting or Advisory Role - Daiichi Sankyo/Astra Zeneca; Pfizer; Pierre Fabre; Seagen
Speakers' Bureau - Daiichi Sankyo/Astra Zeneca; Gilead Sciences; Lilly; Novartis; Pfizer; Roche
Research Funding - Roche (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Gilead Sciences; Pfizer; Roche
(OPTIONAL) Uncompensated Relationships - SOLTI
 
Carmen Hinojo
No Relationships to Disclose
 
Javier Pascual
Honoraria - AstraZeneca; Novartis; Pfizer
Consulting or Advisory Role - AstraZeneca
Travel, Accommodations, Expenses - AstraZeneca; Gilead Sciences; Pfizer
 
Sercan Aksoy
Honoraria - AstraZeneca; Bristol Myers Squibb; Lilly; Merck, Merck Sharp & Dohme; Novartis; Pfizer; Roche
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Lilly; MSD Oncology; Novartis; Pfizer
 
Glen Clack
Employment - Carrick Therapeutics
Stock and Other Ownership Interests - Carrick Therapeutics
 
Stuart McIntosh
Employment - Carrick Therapeutics
Stock and Other Ownership Interests - Carrick Therapeutics